$3,115.81 general Payment -- Regeneron Pharmaceuticals to Dr. Joseph Carter
Regeneron Pharmaceuticals payment to Ophthalmologist Joseph Carter for Tagrisso-related services
This page provides a detailed analysis of a $3,115.81 general payment from Regeneron Pharmaceuticals to Dr. Joseph Carter. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $3,115.81 |
| Payment Type | general |
| Payment Nature | Compensation for services other than consulting |
| Pharmaceutical Company | Regeneron Pharmaceuticals |
| Physician | Dr. Joseph Carter |
| NPI Number | 1786815691 |
| Physician Specialty | Ophthalmology |
| Location | City, MN |
| Date of Payment | 2025-08-30 |
| Related Drug/Device | Tagrisso |
| Conflict Assessment | Low -- Routine |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Regeneron Pharmaceuticals made a $3.1K general payment to Joseph Carter, a Ophthalmology specialist in City, MN. The payment was associated with Tagrisso. The payment of $3,115.81 to Dr. Joseph Carter from Regeneron Pharmaceuticals is for services other than consulting. The payment is associated with the drug Tagrisso, a medication used in oncology. The payment was made on August 30, 2025, in Minnesota.
Patient Guidance: What This Payment Means for You
This payment is for services rendered by your physician and is not related to your personal treatment or prescription decisions. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments to ophthalmologists for services other than consulting are generally less common than those for speaking or consulting, but the amount is within a typical range for service-based compensation.
Regulatory Context: Sunshine Act Requirements
This payment is subject to reporting requirements under the Physician Payments Sunshine Act, which mandates disclosure of payments made by manufacturers of drugs, devices, and biologics to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- cms-open-payments
- regeneron-pharmaceuticals
- joseph-carter
- tagrisso
- ophthalmology
- payment-for-services
Understanding general Payments
general payments are one of several categories of financial transfers from pharmaceutical and medical device companies to physicians that must be reported under the Sunshine Act. Understanding the type and context of a payment is important for evaluating its significance. Not all payments are equal -- a research grant has very different implications than a promotional speaking fee.
Frequently Asked Questions About This Payment
What was this $3.1K payment for?
This was a general payment of $3.1K from Regeneron Pharmaceuticals to Joseph Carter, categorized as "Compensation for services other than consulting". It was associated with Tagrisso. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Joseph Carter accept pharmaceutical money?
Yes, Joseph Carter received this $3.1K payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Joseph Carter's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this general payment?
A general payment of $3.1K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Ophthalmology?
To compare this payment against Ophthalmology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Ophthalmology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Joseph Carter's relationship with Regeneron Pharmaceuticals?
The payment type is 'general', indicating it's not tied to specific research or speaking engagements. This $3.1K general payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Ophthalmology?
The payment nature specifies 'Compensation for services other than consulting', suggesting a service-based arrangement.
What should patients do after learning about this payment?
This payment is for services rendered by your physician and is not related to your personal treatment or prescription decisions.
What else should I know about this general payment?
The drug 'Tagrisso' is listed, which is an oncology drug, potentially indicating a connection to cancer treatment.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.